In Brief: Nexstar/Fujisawa AmBisome
Executive Summary
Nexstar/Fujisawa AmBisome: Liposomal amphotericin B NDA (50-740) for empirical therapy of presumed fungal infection in febrile neutropenic patients will be reviewed by FDA's Antiviral Drugs Advisory Committee July 16. On July 14 and 15, committee will discuss utility of plasma HIV RNA measurement as an endpoint in clinical trials of HIV therapies. The meeting will begin at 8:30 a.m. each day at Armory Place in Silver Spring, Md...
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth